02:05 PM EDT, 05/30/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We keep our target at $973, on 32.9x our 2026 EPS estimate, a discount to LLY's five-year historical forward P/E average. We raise our 2025 EPS estimate to $22.31 from $22.25 and 2026's to $29.53 from $29.35. We see Eli Lilly ( LLY ) as a key beneficiary of the recent decision in the U.S. (May 22) to halt the sale of compounded GLP-1s. Since 2024, Eli Lilly ( LLY ) has been suing several GLP-1 compound sellers on the grounds that these products were either too similar or unsafe. We expect this decision to favorably impact LLY's Tirzepatide (Mounjaro and Zepbound) sales in the U.S. We also positively view LLY's recent decision to acquire SiteOne Therapeutics, which should bolster LLY's pain treatment pipeline. SiteOne develops small molecule inhibitors to treat pain, which we view as a fast-growing therapy area. In our opinion, the company has a valuable Phase 2 ready R&D asset in its pipeline, the STC-004 Nav 1.8 inhibitor, assessed as a next-generation pain treatment and a viable alternative to opioid treatments.